Crispr Therapeutics (NASDAQ:CRSP) was upgraded by equities research analysts at BidaskClub from a “buy” rating to a “strong-buy” rating in a research note issued on Thursday.
Several other analysts also recently weighed in on the stock. SunTrust Banks raised shares of Crispr Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, January 23rd. Piper Jaffray Companies reissued a “buy” rating and issued a $22.75 price target (down from $39.00) on shares of Crispr Therapeutics in a research note on Wednesday, January 10th. Oppenheimer reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Thursday, December 21st. Finally, Cann reissued a “hold” rating on shares of Crispr Therapeutics in a research note on Sunday, December 10th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, four have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $22.81.
Crispr Therapeutics (NASDAQ:CRSP) opened at $39.45 on Thursday. Crispr Therapeutics has a 1 year low of $11.63 and a 1 year high of $42.90. The stock has a market cap of $1,770.00 and a price-to-earnings ratio of -123.28.
In other news, insider Tyler Dylan-Hyde sold 15,000 shares of the company’s stock in a transaction dated Friday, December 15th. The shares were sold at an average price of $18.90, for a total transaction of $283,500.00. Following the completion of the transaction, the insider now directly owns 130,204 shares of the company’s stock, valued at $2,460,855.60. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Thomas Woiwode sold 1,700 shares of the company’s stock in a transaction dated Friday, November 24th. The shares were sold at an average price of $20.21, for a total transaction of $34,357.00. Following the transaction, the director now directly owns 8,218 shares of the company’s stock, valued at $166,085.78. The disclosure for this sale can be found here. Insiders sold 2,234,504 shares of company stock valued at $44,388,553 over the last three months. 39.98% of the stock is currently owned by insiders.
Large investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its stake in shares of Crispr Therapeutics by 459.7% during the second quarter. Wells Fargo & Company MN now owns 7,987 shares of the company’s stock valued at $128,000 after acquiring an additional 6,560 shares during the last quarter. Creative Planning bought a new position in shares of Crispr Therapeutics during the fourth quarter valued at about $243,000. Capital Investment Advisory Services LLC bought a new position in shares of Crispr Therapeutics during the third quarter valued at about $193,000. Ark Investment Management LLC bought a new position in shares of Crispr Therapeutics during the second quarter valued at about $206,000. Finally, Moloney Securities Asset Management LLC bought a new position in shares of Crispr Therapeutics during the third quarter valued at about $235,000. 22.02% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: “Crispr Therapeutics (CRSP) Raised to Strong-Buy at BidaskClub” was originally posted by American Banking News and is the property of of American Banking News. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.americanbankingnews.com/2018/01/28/crispr-therapeutics-crsp-raised-to-strong-buy-at-bidaskclub.html.
About Crispr Therapeutics
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.